Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vadastuximab Talirine with Allo-SCT in Relapsed/Refractory AML
NCT02614560Phase 2Terminated
- Sponsor
- Seagen Inc.
- Start
- Nov 2015
- Primary completion
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vadastuximab talirine in acute myeloid leukemia (AML), sponsored by Seagen Inc.. Started Nov 2015; status: terminated.
02
Drugs
vadastuximab talirine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02614560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02614560.